Search

Displaying results 1041 - 1050 of 4262 in total
  1. Drug

    Doxazosin

    go.drugbank.com/drugs/DB00590
    ApprovedInvestigational

    [A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285]

  2. Drug

    Tixagevimab

    go.drugbank.com/drugs/DB16394
    ApprovedInvestigational

    [A243351, A243361, L39411] Tixagevimab is not approved for any indication by the FDA. … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.

  3. Drug

    Sarecycline

    go.drugbank.com/drugs/DB12035
    ApprovedInvestigational

    Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 … The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well [L4814].

  4. Drug

    Corticotropin

    go.drugbank.com/drugs/DB01285
    ApprovedInvestigationalVet approved

    Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.

  5. Drug

    Sibeprenlimab

    go.drugbank.com/drugs/DB18919
    ApprovedInvestigational

    [A274853, A274858] Sibeprenlimab is a humanized immunoglobulin G2 (IgG2) monoclonal antibody produced by Chinese Hamster Ovary (CHO) cells. … [L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628]

  6. Drug

    Erythropoietin

    go.drugbank.com/drugs/DB00016
    ApprovedInvestigational

    Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alfa and beta formulations. … It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow [FDA Label].

  7. Drug

    Edaravone

    go.drugbank.com/drugs/DB12243
    ApprovedInvestigational

    [L44007] The oral suspension formulation of edaravone was approved by the FDA in May 2022 and by Health Canada in November 2022. … [L44017] Edaravone was initially granted orphan designation by the European Medicines Agency on June 19, 2015 [L44007] and was under regulatory review in Europe.

  8. Drug

    Clindamycin

    go.drugbank.com/drugs/DB01190
    ApprovedInvestigationalVet approved

    Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity tha...

  9. Drug

    Hydrocodone

    go.drugbank.com/drugs/DB00956
    ApprovedIllicitInvestigational

    Historically, hydrocodone has been used as a cough suppressant although this has largely been replaced by [dextromethorphan] in current cough and cold formulations.

  10. Drug

    Bimatoprost

    go.drugbank.com/drugs/DB00905
    ApprovedInvestigational

    Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. … [L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug